Upcoming Dividend • Jun 08
Upcoming dividend of CN¥0.20 per share Eligible shareholders must have bought the stock before 15 June 2026. Payment date: 11 August 2026. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Hong Kong dividend payers (6.9%). Lower than average of industry peers (3.5%). Announcement • Apr 23
Shanghai Conant Optical Co., Ltd. (SEHK:2276) completed the acquisition of remaining 51% stake in Jiangsu Blue Optics Lens Co., Ltd. Shanghai Conant Optical Co., Ltd. (SEHK:2276) entered a share transfer agreement to acquire remaining 51% stake in Jiangsu Blue Optics Lens Co., Ltd. for CNY 72 million on December 31, 2025. A cash consideration of CNY 72 million will be paid by Shanghai Conant Optical Co., Ltd. As part of consideration, CNY 72 million is paid towards common equity of Jiangsu Blue Optics Lens Co., Ltd. Upon completion, Shanghai Conant Optical Co., Ltd. will own 100% stake in Jiangsu Blue Optics Lens Co., Ltd.
Shanghai Conant Optical Co., Ltd. (SEHK:2276) completed the acquisition of remaining 51% stake in Jiangsu Blue Optics Lens Co., Ltd. on April 22, 2026. Reported Earnings • Apr 04
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: CN¥1.20 (up from CN¥1.03 in FY 2024). Revenue: CN¥2.19b (up 6.1% from FY 2024). Net income: CN¥557.7m (up 30% from FY 2024). Profit margin: 26% (up from 21% in FY 2024). Revenue missed analyst estimates by 6.9%. Earnings per share (EPS) exceeded analyst estimates by 1.1%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 02
Shanghai Conant Optical Co., Ltd. Proposes Final Dividend for Year Ended 31 December 2025, Payable No Later Than 11 August 2026 Shanghai Conant Optical Co., Ltd. recommends the payment of a final dividend of RMB 0.20 (tax inclusive) per ordinary share for the year ended 31 December 2025 (the"Proposed Final Dividend") (for the year ended 31 December 2024: RMB 0.16 per share) together with the interim dividend of RMB 0.15 per share for 2025, the total dividend declared in 2025 would be RMB 0.35 per share. Subject to the approval of shareholders of the Company (the "Shareholders") at the annual general meeting to be held on 11 June 2026, the Proposed Final Dividend will be paid to the Shareholders whose names appear on the register of members of the Company on Wednesday, 24 June 2026. The Proposed Final Dividend will be declared in Renminbi and paid in Hong Kong dollars based on the average exchange rate of Renminbi against Hong Kong dollars published by the People's Bank of China five business days prior to the date of the AGM. The Proposed Final Dividend is expected to be distributed to the Shareholders no later than 11 August 2026. Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to HK$42.50, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 18x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 811% over the past three years. Announcement • Mar 31
Shanghai Conant Optical Co., Ltd., Annual General Meeting, Jun 11, 2026 Shanghai Conant Optical Co., Ltd., Annual General Meeting, Jun 11, 2026. Announcement • Mar 11
Shanghai Conant Optical Co., Ltd. to Report Fiscal Year 2025 Results on Mar 30, 2026 Shanghai Conant Optical Co., Ltd. announced that they will report fiscal year 2025 results on Mar 30, 2026 Announcement • Feb 04
Shanghai Conant Optical Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.404 billion. Shanghai Conant Optical Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.404 billion.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 27,000,000
Price\Range: HKD 52
Discount Per Security: HKD 0.013
Transaction Features: Subsequent Direct Listing Valuation Update With 7 Day Price Move • Jan 20
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to HK$62.15, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 21x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 1,309% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$50.40 per share. Buy Or Sell Opportunity • Jan 19
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 56% to HK$62.05. The fair value is estimated to be HK$50.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 48% in the next 2 years. Announcement • Jan 16
Shanghai Conant Optical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2025 Shanghai Conant Optical Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2025. For the year, the Group expected its net profit attributable to shareholders for the year ended 31 December 2025 to increase by no less than 30% compared with that for the year ended 31 December 2024. The increase was mainly attributable to (i) higher sales of lenses with refractive index of 1.74 and other multifunctional products; (ii) the Company's increased economies of scale and the enhancement of the Company's level of automation; and (iii) the Company's proactive efforts to optimize financing structure, enhance capital return and reduce financing costs. Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to HK$54.85, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 16x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 1,088% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$73.42 per share. Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to HK$44.40, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 17x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 761% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$74.77 per share. Upcoming Dividend • Sep 04
Upcoming dividend of CN¥0.15 per share Eligible shareholders must have bought the stock before 11 September 2025. Payment date: 15 October 2025. Payout ratio is a comfortable 28% and the cash payout ratio is 83%. Trailing yield: 0.8%. Lower than top quartile of Hong Kong dividend payers (6.7%). Lower than average of industry peers (2.2%). Valuation Update With 7 Day Price Move • Aug 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to HK$47.56, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 18x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 825% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$73.85 per share. Declared Dividend • Aug 12
First half dividend of CN¥0.15 announced Shareholders will receive a dividend of CN¥0.15. Ex-date: 11th September 2025 Payment date: 15th October 2025 Dividend yield will be 0.8%, which is lower than the industry average of 3.0%. Payout Ratios Payout ratio: 28%. Cash payout ratio: 61%. Announcement • Jul 24
Shanghai Conant Optical Co., Ltd. to Report First Half, 2025 Results on Aug 08, 2025 Shanghai Conant Optical Co., Ltd. announced that they will report first half, 2025 results on Aug 08, 2025 Announcement • Jul 08
Shanghai Conant Optical Co., Ltd. Provides Group Earnings Guidance for the Six Months Ended 30 June 2025 Shanghai Conant Optical Co., Ltd. provided group earnings guidance for the six months ended 30 June 2025. For the period, the Group expects its net profit attributable to its shareholders to increase by no less than 30% compared with that for the six months ended 30 June 2024, which is mainly due to the strong growth in sales volume of high refractive index products and functional products, increased ASP driven by favourable product mix. Upcoming Dividend • Jun 13
Upcoming dividend of CN¥0.16 per share Eligible shareholders must have bought the stock before 20 June 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Hong Kong dividend payers (7.5%). Lower than average of industry peers (2.4%). Announcement • Jun 12
Shanghai Conant Optical Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2024, Payable on or Before 11 August 2025 Shanghai Conant Optical Co., Ltd. announced at the AGM held on June 12, 2025, approved final dividend of RMB 0.16 (tax inclusive) per ordinary share for the year ended 31 December 2024 (the "Final Dividend") was approved at the AGM. The Final Dividend will be paid to the Shareholders whose names appear on the register of members of the Company on 30 June 2025. The Final Dividend will be declared in Renminbi and paid in Hong Kong dollars based on the average exchange rate of Renminbi against Hong Kong dollars published by the People's Bank of China five business days prior to the date of the AGM, which is RMB 1 equivalent to HKD 1.0922. Therefore, the Final Dividend per ordinary share is HKD 0.1748 (tax inclusive). The Final Dividend is expected to be distributed to the Shareholders on or before 11 August 2025. Valuation Update With 7 Day Price Move • May 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to HK$31.10, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 17x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 644% over the past three years. Reported Earnings • May 01
Full year 2024 earnings released: EPS: CN¥1.03 (vs CN¥0.77 in FY 2023) Full year 2024 results: EPS: CN¥1.03 (up from CN¥0.77 in FY 2023). Revenue: CN¥2.06b (up 17% from FY 2023). Net income: CN¥428.3m (up 31% from FY 2023). Profit margin: 21% (up from 19% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Apr 07
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 21% to HK$21.05. The fair value is estimated to be HK$27.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 21%. Revenue is forecast to grow by 34% in 2 years. Earnings are forecast to grow by 46% in the next 2 years. Declared Dividend • Apr 02
Final dividend of CN¥0.16 announced Shareholders will receive a dividend of CN¥0.16. Ex-date: 20th June 2025 Payment date: 11th August 2025 Dividend yield will be 1.1%, which is lower than the industry average of 3.0%. Reported Earnings • Apr 01
Full year 2024 earnings released: EPS: CN¥1.03 (vs CN¥0.77 in FY 2023) Full year 2024 results: EPS: CN¥1.03 (up from CN¥0.77 in FY 2023). Revenue: CN¥2.06b (up 17% from FY 2023). Net income: CN¥428.3m (up 31% from FY 2023). Profit margin: 21% (up from 19% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 01
Shanghai Conant Optical Co., Ltd. Proposes Ordinary Final Dividend for the Year Ended 31 December 2024, Payable on 11 August 2025 Shanghai Conant Optical Co., Ltd. proposed the ordinary final dividend of RMB 0.16 per share for the year ended 31 December 2024, payable on 11 August 2025. Ex-dividend date is on 20 June 2025 with Record date on 30 June 2025. Date of shareholders' approval on 12 June 2025. Announcement • Mar 31
Shanghai Conant Optical Co., Ltd., Annual General Meeting, Jun 12, 2025 Shanghai Conant Optical Co., Ltd., Annual General Meeting, Jun 12, 2025. Announcement • Mar 12
Shanghai Conant Optical Co., Ltd. to Report Fiscal Year 2024 Results on Mar 31, 2025 Shanghai Conant Optical Co., Ltd. announced that they will report fiscal year 2024 results on Mar 31, 2025 Announcement • Feb 28
Shanghai Conant Optical Co., Ltd. Approves Board Appointments Shanghai Conant Optical Co., Ltd. announced at EGM held on February 28, 2025, the shareholders approved appointment of Ms. Cao Xue as an executive Director, Mr. Tian Kehan as a non- executive Director and Mr. Jin Yiting as an independent non-executive Director. Following the approval by the Shareholders at the EGM, the appointment of Ms. Cao Xue as an executive Director, Mr. Tian Kehan as a non-executive Director and Mr. Jin Yiting as an independent non-executive Director has become effective in accordance with the Articles of Association. Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$28.00, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 10x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 590% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$49.99 per share. New Risk • Jan 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Jan 17
Shanghai Conant Optical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2024 Shanghai Conant Optical Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2024. For the year, group expected its net profit attributable to shareholders for the year ended 31 December 2024 to increase by no less than 30% compared with that for the year ended 31 December 2023. The increase was mainly attributable to (i) the remarkable results achieved by the Company in business market expansion, resulting in steady revenue growth; (ii) diversified lens types increased the proportion of high value-added products; and (iii) the Company's continued efforts to optimize its financing structure and scale, improve profit margins, and reduce financing costs, resulting in a further decrease in finance costs. Announcement • Jan 07
Shanghai Conant Optical Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 845.7345 million. Shanghai Conant Optical Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 845.7345 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 53,325,000
Price\Range: HKD 15.86
Transaction Features: Subsequent Direct Listing Announcement • Dec 24
Shanghai Conant Optical Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 845.7345 million. Shanghai Conant Optical Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 845.7345 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 53,325,000
Price\Range: HKD 15.86
Transaction Features: Subsequent Direct Listing Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to HK$15.62, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 271% over the past three years. Announcement • Sep 11
Shanghai Conant Optical Co., Ltd. Approves Interim Dividend for the Six Months Ended 30 June 2024, Payable on 15 October 2024 Shanghai Conant Optical Co., Ltd. at its EGM held on 9 September 2024 considered and approved the payment of an interim dividend for the six months ended 30 June 2024 of RMB 0.12 per share of the Company (tax inclusive). Ex-dividend date: 12 September 2024. Record date: 19 September 2024. Payment date: 15 October 2024. Reported Earnings • Sep 08
First half 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.37 in 1H 2023) First half 2024 results: EPS: CN¥0.50 (up from CN¥0.37 in 1H 2023). Revenue: CN¥976.4m (up 18% from 1H 2023). Net income: CN¥208.7m (up 32% from 1H 2023). Profit margin: 21% (up from 19% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong. Upcoming Dividend • Sep 05
Upcoming dividend of CN¥0.12 per share Eligible shareholders must have bought the stock before 12 September 2024. Payment date: 15 October 2024. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Hong Kong dividend payers (8.4%). Lower than average of industry peers (4.0%). Reported Earnings • Aug 07
First half 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.37 in 1H 2023) First half 2024 results: EPS: CN¥0.50 (up from CN¥0.37 in 1H 2023). Revenue: CN¥976.4m (up 18% from 1H 2023). Net income: CN¥208.7m (up 32% from 1H 2023). Profit margin: 21% (up from 19% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in Hong Kong. Buy Or Sell Opportunity • Aug 05
Now 23% undervalued Over the last 90 days, the stock has risen 21% to HK$10.74. The fair value is estimated to be HK$13.90, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period. Upcoming Dividend • Jun 05
Upcoming dividend of CN¥0.20 per share Eligible shareholders must have bought the stock before 12 June 2024. Payment date: 02 August 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Hong Kong dividend payers (7.6%). Lower than average of industry peers (3.4%). Announcement • Jun 05
Shanghai Conant Optical Co., Ltd. Approves the Final Cash Dividend for the Year Ended December 31, 2023, Payable on or Before 2 August 2024 Shanghai Conant Optical Co., Ltd. announced the payment of a final dividend of RMB 0.20 (tax inclusive) per ordinary share for the year ended 31 December 2023 (the "Final Dividend") was approved at the AGM. The Final Dividend will be paid to the Shareholders whose names appear on the register of members of the Company on 20 June 2024. The Final Dividend will be declared in Renminbi and paid in Hong Kong dollars based on the average exchange rate of Renminbi against Hong Kong dollars published by the People's Bank of China five business days prior to the date of the AGM, which is RMB1 equivalent to HKD 1.10. Therefore, the Final Dividend per ordinary share is HKD 0.22 (tax inclusive). The Final Dividend is expected to be distributed to the Shareholders on or before 2 August 2024. For determining the entitlement of the Shareholders to receive the Proposed Final Dividend, the Company's register of members will be closed from 14 June 2024 to 20 June 2024, both days inclusive, during which period no transfer of share will be registered. In order to be eligible to receive the Proposed Final Dividend, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on 13 June 2024. Valuation Update With 7 Day Price Move • May 28
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$10.14, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 10x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 91% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$11.83 per share. Reported Earnings • Apr 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.77 (up from CN¥0.58 in FY 2022). Revenue: CN¥1.76b (up 13% from FY 2022). Net income: CN¥327.0m (up 32% from FY 2022). Profit margin: 19% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) also missed analyst estimates by 2.7%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong. Announcement • Mar 28
Shanghai Conant Optical Co., Ltd., Annual General Meeting, Jun 04, 2024 Shanghai Conant Optical Co., Ltd., Annual General Meeting, Jun 04, 2024. Agenda: To consider approval of Final Dividend. Reported Earnings • Mar 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.77 (up from CN¥0.58 in FY 2022). Revenue: CN¥1.76b (up 13% from FY 2022). Net income: CN¥327.0m (up 32% from FY 2022). Profit margin: 19% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) also missed analyst estimates by 2.7%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong. Announcement • Mar 27
Shanghai Conant Optical Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 02, 2024 Shanghai Conant Optical Co., Ltd. proposed final ordinary dividend of RMB 0.2 per share for the year ended December 31, 2023. Ex-dividend date is June 12, 2024. Record date is June 20, 2024 and The dividend will be payable on August 02, 2024. Date of shareholders' approval will be 04 June 2024. Announcement • Mar 05
Shanghai Conant Optical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024 Shanghai Conant Optical Co., Ltd. announced that they will report fiscal year 2023 results on Mar 27, 2024 Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to HK$7.10, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 15x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 53% over the past year. Announcement • Nov 30
Shanghai Conant Optical Co., Ltd. Announces Executive Changes, Effective from 1 December 2023 Shanghai Conant Optical Co., Ltd. announced the resignation of Ms. Lin Sio Ngo and the appointment of Mr. Chan Pui Hang as the Joint Company Secretary, the Authorised Representative and the Process Agent of the Company with effect from 1 December 2023. Ms. Lin has confirmed that she has no disagreement with the Board and there is no matter relating to her resignations that needs to be brought to the attention of the Stock Exchange or the shareholders of the Company. Ms. Cao Xue will continue to serve as the other Joint Company Secretary. Ms. Cao has over eight years of experience in the resin spectacle lens industry. She has extensive knowledge about the business operations, corporate culture and matters concerning the corporate governance of the Company. Ms. Cao joined the Group in October 2013 and was responsible for the accounting and financial management of Shanghai Conant Optics Co., Ltd. until December 2015. She served as a financial supervisor of Shanghai Conant from January 2016 to December 2020 and was appointed as the manager of overseas asset management department of Shanghai Conant in January 2021. She has also served as a director of Asahi Lite Holdings Limited since May 2017 and a director of Asahi Lite Optical Co., Ltd. since April 2021. Ms. Cao obtained a bachelor's degree in literature majoring in Japanese from Tongji University in July 2013 and a master's degree of Master of Corporate Governance from Hong Kong Metropolitan University in September 2023.Mr. Chan is currently a solicitor at the law firm of Michael Li & Co. in Hong Kong, specialising in corporate finance work including initial public offerings, mergers and acquisitions and restructuring. Mr. Chan is a practising solicitor and was admitted as a solicitor in Hong Kong in December 2011. He received a degree of Bachelor of Social Science (Government & Laws) and a degree of Bachelor of Laws from the University of Hong Kong in December 2002 and December 2003 respectively. Reported Earnings • Aug 13
First half 2023 earnings released: EPS: CN¥0.37 (vs CN¥0.28 in 1H 2022) First half 2023 results: EPS: CN¥0.37 (up from CN¥0.28 in 1H 2022). Revenue: CN¥831.2m (up 11% from 1H 2022). Net income: CN¥158.6m (up 34% from 1H 2022). Profit margin: 19% (up from 16% in 1H 2022). The increase in margin was driven by higher revenue. Announcement • Aug 03
Shanghai Conant Optical Co., Ltd. to Report First Half, 2023 Results on Aug 11, 2023 Shanghai Conant Optical Co., Ltd. announced that they will report first half, 2023 results on Aug 11, 2023 Announcement • Jul 23
Shanghai Conant Optical Co., Ltd. Provides Earning Guidance for Six Months Ended 30 June 2023 Shanghai Conant Optical Co., Ltd. provided earning guidance for six months ended 30 June 2023. The board of directors of the Company informed the shareholders and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 (the "First Half of 2023") and the information currently available to the Board, the Group expectsits net profit attributable to shareholders for the First Half of 2023 to increase by no less than 30% compared with that for the six months ended 30 June 2022, which is mainly due to the fact that (i) the product sales and sales volume increase as a result of the continuous expansion of the sales business in the First Half of 2023; (ii) upon the commencement of the production capacity enhancing projects under intended use of net proceeds, their effectiveness gradually becomes apparent, thereby leading to a relatively faster boost in the sales generated from the business models of lens customization and one-stop integrated services, which is conducive to the increase in the general sales and profit; (iii) the reduction of financial expenses and interest expenses allows the Group to reasonably optimize the financing scale, which in turn reduces financing cost; and (iv) the fluctuation in the global currency market leads to an increase in exchange gain due to the U.S. dollar appreciation. Announcement • Jun 15
Shanghai Conant Optical Co., Ltd. Approves the Payment of Final Dividend for the Year Ended December 31, 2022, Expected to Be Distributed to the Shareholders on or Before 15 August 2023 Shanghai Conant Optical Co., Ltd. approved the payment of a final dividend of RMB 0.15 (tax inclusive) per ordinary share for the year ended December 31, 2022 was approved at the AGM. The Final Dividend will be paid to the Shareholders whose names appear on the register of members of the Company on 27 June 2023. The Final Dividend will be declared in Renminbi and paid in Hong Kong dollars based on the average exchange rate of Renminbi against Hong Kong dollars published by the People's Bank of China five business days prior to the date of the AGM, which is RMB 1 equivalent to HK 1.1000. Therefore, the Final Dividend per ordinary share is HKD 0.1650 (tax inclusive). The Final Dividend is expected to be distributed to the Shareholders on or before 15 August 2023. Upcoming Dividend • Jun 09
Upcoming dividend of CN¥0.15 per share at 3.1% yield Eligible shareholders must have bought the stock before 16 June 2023. Payment date: 15 August 2023. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 3.1%. Lower than top quartile of Hong Kong dividend payers (7.7%). Higher than average of industry peers (1.7%). Announcement • May 24
Shanghai Conant Optical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 15 August 2023 Shanghai Conant Optical Co., Ltd. at the AGM to be held on 14 June 2023, proposed the payment of a final dividend for the year ended 31 December 2022 of RMB 0.15 per share (tax inclusive). The final dividend, if approved by the Shareholders at the AGM, will be paid on or before 15 August 2023 to the Shareholders whose names appear on the register of members of the Company on 27 June 2023. Reported Earnings • Mar 18
Full year 2022 earnings released: EPS: CN¥0.58 (vs CN¥0.59 in FY 2021) Full year 2022 results: EPS: CN¥0.58. Revenue: CN¥1.56b (up 15% from FY 2021). Net income: CN¥248.6m (up 35% from FY 2021). Profit margin: 16% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Announcement • Feb 10
Shanghai Conant Optical Co., Ltd. Provides Earnings Guidance for the Year Ended 31 December 2022 Shanghai Conant Optical Co., Ltd. provides earnings guidance for the year ended 31 December 2022. The Group is expected to record an increase of no less than 30% in net profit attributable to shareholders for the year ended 31 December 2022, as compared to that for the year ended 31 December 2021. The increase was mainly attributable to (i) an increase in revenue as a result of an increase in the sale volume of resin spectacle lens; (ii) an increase in exchange gain arising from the appreciation of U.S. dollar against Renminbi; and (iii) a decrease in finance costs due to the repayment of interest-bearing bank borrowings and the reduction in the interest rates of bank borrowing. Announcement • Dec 17
Shanghai Conant Optical Co., Ltd. Appoints Zhao Xiaoyun as a Non-Executive Director Shanghai Conant Optical Co., Ltd. announced that at the EGM held on 16 December 2022 approved the appointment of Ms. Zhao Xiaoyun as a non-executive director of the Company with the term of office commencing from 16 December 2022 until expiry of the term of the current session of the Board. Ms. Zhao Xiaoyun, aged 50, is currently the supervisor (part-time) of Asahi Optical Co., Ltd, an indirect wholly-owned subsidiary of the Company. Prior to joining the Group in April 2018, Ms. Zhao worked in a number of financial consultancy, asset management and securities companies in the PRC as their legal representative and/or financial controller. Ms. Zhao holds a Bachelor of Arts in Literature from Waseda University in Japan. She passed the examination for the securities qualification issued by the Securities Association of China in September 2009 and the fund qualification issued by the Asset Management Association of China in June 2018, and possesses the accounting qualification (intermediate level) issued by the Ministry of Personnel of the PRC in May 2007. Ms. Zhao's appointment was recommended by the nomination committee of the Company after taking into account her previous work experience and her expected devotion to the Company in terms of time and effort. Taking into consideration of the diversity perspectives (including but not limited to gender, age, cultural and educational background, professional experience, length of service, skills and knowledge), the Board is satisfied that Ms. Zhao is of such character, integrity and experience which commensurate with the office of a non-executive Director. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Chairman of Supervisory Board Chuanbao Wang was the last director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Buying Opportunity • Aug 30
Now 21% undervalued Over the last 90 days, the stock is up 20%. The fair value is estimated to be HK$7.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last year. Earnings per share has grown by 16%. Buying Opportunity • Aug 03
Now 20% undervalued Over the last 90 days, the stock is up 25%. The fair value is estimated to be HK$6.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last year. Earnings per share has grown by 41%. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment improved over the past week After last week's 18% share price gain to HK$5.75, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 16x in the Medical Equipment industry in Hong Kong. Reported Earnings • May 04
Full year 2021 earnings released: EPS: CN¥0.59 (vs CN¥0.42 in FY 2020) Full year 2021 results: EPS: CN¥0.59 (up from CN¥0.42 in FY 2020). Revenue: CN¥1.36b (up 24% from FY 2020). Net income: CN¥183.5m (up 43% from FY 2020). Profit margin: 14% (up from 12% in FY 2020). The increase in margin was driven by higher revenue. Announcement • Apr 23
Shanghai Conant Optical Co., Ltd. Appoints Wang Chuanbao as Chairman of the Current Session of the Supervisory Committee Shanghai Conant Optical Co., Ltd. announced that at the EGM was held on April 22, 2022, the company approved the Mr. Wang Chuanbao was elected as the chairman of the current session of the Supervisory Committee, with the term of office commencing from 22 April 2022 until expiry of the term of the current session of the Supervisory Committee. Announcement • Apr 20
Shanghai Conant Optical Co., Ltd. to Report Fiscal Year 2021 Results on Apr 22, 2022 Shanghai Conant Optical Co., Ltd. announced that they will report fiscal year 2021 results on Apr 22, 2022